SG10202101055VA - Spiro-lactam nmda receptor modulators and uses thereof - Google Patents

Spiro-lactam nmda receptor modulators and uses thereof

Info

Publication number
SG10202101055VA
SG10202101055VA SG10202101055VA SG10202101055VA SG10202101055VA SG 10202101055V A SG10202101055V A SG 10202101055VA SG 10202101055V A SG10202101055V A SG 10202101055VA SG 10202101055V A SG10202101055V A SG 10202101055VA SG 10202101055V A SG10202101055V A SG 10202101055VA
Authority
SG
Singapore
Prior art keywords
spiro
nmda receptor
receptor modulators
lactam nmda
lactam
Prior art date
Application number
SG10202101055VA
Other languages
English (en)
Inventor
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of SG10202101055VA publication Critical patent/SG10202101055VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10202101055VA 2016-08-01 2017-08-01 Spiro-lactam nmda receptor modulators and uses thereof SG10202101055VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662369453P 2016-08-01 2016-08-01

Publications (1)

Publication Number Publication Date
SG10202101055VA true SG10202101055VA (en) 2021-03-30

Family

ID=59582038

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202101055VA SG10202101055VA (en) 2016-08-01 2017-08-01 Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA SG11201900443VA (en) 2016-08-01 2017-08-01 Spiro-lactam nmda receptor modulators and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201900443VA SG11201900443VA (en) 2016-08-01 2017-08-01 Spiro-lactam nmda receptor modulators and uses thereof

Country Status (17)

Country Link
US (3) US11299495B2 (fr)
EP (1) EP3490992B1 (fr)
JP (2) JP2019527233A (fr)
KR (1) KR102465758B1 (fr)
CN (1) CN109937204B (fr)
AU (2) AU2017306152A1 (fr)
BR (1) BR112019001768A2 (fr)
CA (1) CA3031537A1 (fr)
CL (1) CL2019000248A1 (fr)
CO (1) CO2019000945A2 (fr)
EA (1) EA201990424A1 (fr)
IL (1) IL264514B (fr)
MX (1) MX2019001319A (fr)
PE (1) PE20190503A1 (fr)
PH (1) PH12019500202A1 (fr)
SG (2) SG10202101055VA (fr)
WO (1) WO2018026779A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553968T3 (es) 2008-09-18 2015-12-15 Northwestern University Moduladores del receptor NMDA y sus usos
KR102280616B1 (ko) 2013-01-29 2021-07-21 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
MX2019001319A (es) 2016-08-01 2019-07-04 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
WO2018026792A1 (fr) 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs spiro-lactames et bis-spiro-lactames des récepteurs nmda et leurs utilisations
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
PE20211455A1 (es) * 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
CN112204031B (zh) * 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
CN109608460A (zh) * 2018-12-17 2019-04-12 上海合全药业股份有限公司 一种1,10-二氧亚基-2,7-二氮杂螺[4.5]癸烷-7-甲酸叔丁酯的合成方法
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2021228123A1 (fr) * 2020-05-12 2021-11-18 北京广为医药科技有限公司 Composé permettant d'ajuster l'activité du récepteur nmda, composition pharmaceutique et utilisation associées
CN114591326B (zh) * 2022-02-28 2024-02-27 上海筛杰生物医药有限公司 Cct-251921的中间体及其制备方法

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180398A1 (fr) 1984-10-26 1986-05-07 The Regents Of The University Of California Synthèse de bêta-lactame
CA1305177C (fr) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxypropylglycine et procede pour sa production
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (fr) 1988-07-25 1990-03-28 Glaxo Group Limited Dérivés de spirolactames
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
CA2058975C (fr) 1990-10-30 2000-06-06 Shuichi Kasai Preparation antiinflammatoire sous forme de gel
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
BR9709533A (pt) 1996-06-07 1999-08-10 Zeneca Ltd Derivado de peptídeo uso e processo para a produção do mesmo composição farmacéutica processo para o tratamento de uma doença autoimune ou inflamatória mediada por célula t dependente de mhc classe ii e aminoácido protegido ou desprotegido ou um sal do mesmo
AU3972797A (en) 1996-08-02 1998-02-25 Zymogenetics Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
WO2000027790A1 (fr) 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Composes a base de mutiline
US6194158B1 (en) 1998-11-12 2001-02-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001036685A2 (fr) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Expression differentielle de genes dans le cancer
AU782678B2 (en) 2000-02-01 2005-08-18 Agy Therapeutics, Inc. Interaction of NMDA receptor with protein tyrosine phosphatase
JP2001261679A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
WO2001096606A2 (fr) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification de genes et de composes pour le traitement du cancer
AU2001271366A1 (en) 2000-06-22 2002-01-02 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1186303A3 (fr) 2000-09-06 2003-12-10 Pfizer Products Inc. Combinaisons pharmaceutiques pour le traitement des accidents cerebrovasculaires, contenant un facteur inhibitant la neutrophile et un antagoniste selectif du NMDA-NR2B
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
AU2002236608A1 (en) 2000-12-14 2002-06-24 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
US20030065138A1 (en) 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
WO2002072609A2 (fr) 2001-03-12 2002-09-19 Nyxis Neurotherapies, Inc Peptides neuroactifs utilises dans la prevention et/ou le traitement de l'hypoxie et de la douleur neuropathique
WO2003010540A1 (fr) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Procede d'identification d'un agent lie au nmda
JP4749715B2 (ja) 2002-07-05 2011-08-17 ターガセプト，インコーポレイテッド Ｎ−アリールジアザスピロ環式化合物、並びにその製造及び使用方法
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004094371A2 (fr) 2003-04-17 2004-11-04 Merck & Co., Inc. Modulateurs tetrahydroisoquinoline et tetrahydropyridopyridine cyclopentyles heterocycliques de l'activite des recepteurs de chimiokine
WO2005007656A1 (fr) 2003-07-18 2005-01-27 Virochem Pharma Inc. Composes spiro et procedes pour moduler une activite de recepteur de chimiokime
CA2534909A1 (fr) 2003-08-08 2005-02-17 The Burnham Institute Regulation des recepteurs de nmda mediee par la proteine p16
WO2005020973A2 (fr) 2003-08-29 2005-03-10 The University Of Houston System Compositions a activite antimycobacterienne comprenant un hydroxamate ou un hydroxamate et une hydroxylamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2005047286A1 (fr) 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. Compose spiranique heterocyclique
RU2355690C2 (ru) 2004-01-08 2009-05-20 Ф.Хоффманн-Ля Рош Аг Производные диазаспиропиперидина
US20060058328A1 (en) * 2004-08-20 2006-03-16 Bhatti Balwinder S Use of N-aryl diazaspiracyclic compounds in the treatment of addiction
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
CN101090902B (zh) 2004-10-13 2013-05-29 默沙东公司 Cgrp受体拮抗剂
DK2030622T3 (da) 2005-03-24 2011-05-02 Univ Emory Doseringsangivelse af progesteron i behandlingen af en traumatisk hjerneskade
WO2007025141A2 (fr) 2005-08-26 2007-03-01 Wisconsin Alumni Research Foundation Poly-beta-peptides a partir de monomeres de beta-lactame fonctionnalises ainsi que compositions antibacteriennes contenant ceux-ci
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US7884080B2 (en) 2006-09-15 2011-02-08 Schering Plough Corporation Azetidinone derivatives and methods of use thereof
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
MX2009010037A (es) 2007-03-20 2009-11-05 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasas.
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009039390A2 (fr) 2007-09-20 2009-03-26 Naurex Inc. Développement de procédés thérapeutiques à base de glycobiologie pour le traitement de tumeurs cérébrales
WO2009105718A1 (fr) 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Modifications génétiques associées à l'autisme et au phénotype autistique et procédés d'utilisation de celles-ci pour le diagnostic et le traitement de l'autisme
BRPI0914687A2 (pt) 2008-06-24 2015-10-20 Intervet Int Bv preparação veterinária por derramamento, métodos para tratar condições inflamatórias e para administrar a preparação veterinária por derramamento, e, uso da preparação veterinária por derramamento
US20110136862A1 (en) 2008-06-27 2011-06-09 Neurosearch A/S Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AU2009278075B2 (en) 2008-08-07 2013-07-04 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
GB0814991D0 (en) 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
ES2553968T3 (es) 2008-09-18 2015-12-15 Northwestern University Moduladores del receptor NMDA y sus usos
WO2010065709A2 (fr) 2008-12-03 2010-06-10 Amin Khan Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
US8329904B2 (en) 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US20120178695A1 (en) 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
RS53513B1 (en) 2009-10-05 2015-02-27 Northwestern University GLYX-13 FOR USE IN THE REFRACTOR DEPRESSION TREATMENT PROCEDURE
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
ES2459496T3 (es) 2009-12-21 2014-05-09 Novartis Ag Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
ES2706063T3 (es) 2010-02-11 2019-03-27 Univ Northwestern Agonistas del receptor de NMDA y usos del mismo
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
GB201007789D0 (en) * 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
AR082633A1 (es) 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
ES2551592T3 (es) 2011-02-25 2015-11-20 Novartis Ag Pirazolo[1,5-a]piridinas como inhibidores de TRK
TR201802550T4 (tr) * 2011-03-14 2018-03-21 Boehringer Ingelheim Int Lökotrien üretiminin benzodioksan inhibitörleri.
CN103974712A (zh) 2011-04-27 2014-08-06 西北大学 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
CN103635264B (zh) 2011-06-27 2016-06-01 皇家飞利浦有限公司 超声换能组件及其制造方法
US9745332B2 (en) 2011-07-18 2017-08-29 The Governors Of The Univerity Of Alberta Catalysts and processes for the hydrogenation of amides
HUE037645T2 (hu) 2011-07-27 2018-09-28 Astrazeneca Ab Rák kezelésére alkalmas 2.(2,4,5-helyettesített-anilino)pirimidin származékok mint EGFR modulátorok
US9546179B2 (en) 2011-12-20 2017-01-17 Wei Qian Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
CN102936216B (zh) 2012-12-05 2015-03-04 南京药石药物研发有限公司 7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
SG11201505934XA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
MX2015009785A (es) * 2013-01-29 2016-04-04 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
KR102280616B1 (ko) 2013-01-29 2021-07-21 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
BR112015018095A2 (pt) * 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CN103171641B (zh) 2013-03-19 2015-07-15 浙江大学 具备轮动功能的弹跳机器人
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
GB2528480A (en) 2014-07-23 2016-01-27 Givaudan Sa Improvements in or relating to organic compounds
GB201416346D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
CA3024606C (fr) 2016-05-19 2019-09-03 Aptinyx Inc. Modulateurs de recepteurs nmda de spiro-lactame et utilisations associees
WO2017201285A1 (fr) 2016-05-19 2017-11-23 Aptinyx Inc. Modulateurs spirolactames des récepteurs nmda et leurs utilisations
WO2018026792A1 (fr) 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs spiro-lactames et bis-spiro-lactames des récepteurs nmda et leurs utilisations
MX2019001319A (es) 2016-08-01 2019-07-04 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
PE20211455A1 (es) 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20210308101A1 (en) 2019-11-11 2021-10-07 Aptinyx Inc. Methods of treating fibromyalgia
KR20220110251A (ko) 2019-12-04 2022-08-05 앱티닉스 인크. 신경변성 질환과 연관된 인지 장애를 치료하는 방법

Also Published As

Publication number Publication date
JP2019527233A (ja) 2019-09-26
PE20190503A1 (es) 2019-04-10
US20230312591A1 (en) 2023-10-05
SG11201900443VA (en) 2019-02-27
EP3490992B1 (fr) 2023-03-22
AU2017306152A1 (en) 2019-01-31
WO2018026779A1 (fr) 2018-02-08
JP2022120019A (ja) 2022-08-17
MX2019001319A (es) 2019-07-04
CA3031537A1 (fr) 2018-02-08
US11530223B2 (en) 2022-12-20
US20220220119A1 (en) 2022-07-14
IL264514B (en) 2021-09-30
CN109937204B (zh) 2022-11-25
KR102465758B1 (ko) 2022-11-09
IL264514A (en) 2019-02-28
PH12019500202A1 (en) 2019-07-29
CN109937204A (zh) 2019-06-25
EP3490992A1 (fr) 2019-06-05
JP7448766B2 (ja) 2024-03-13
US11299495B2 (en) 2022-04-12
EA201990424A1 (ru) 2019-08-30
BR112019001768A2 (pt) 2019-06-11
KR20190033595A (ko) 2019-03-29
AU2021240150A1 (en) 2021-10-28
CO2019000945A2 (es) 2019-02-08
US20190177334A1 (en) 2019-06-13
CL2019000248A1 (es) 2019-06-21

Similar Documents

Publication Publication Date Title
ZA201807731B (en) Spiro-lactam nmda receptor modulators and uses thereof
IL264514A (en) Spiro-lactam modulates and uses of the nmda receptor
HK1247199A1 (zh) 雌激素受體調節劑及其用途
IL286107A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL264488A (en) Spiro-lactam nmda receptor modulators and uses thereof
ZA201900961B (en) Chemokine receptor modulators and uses thereof
IL276332A (en) Spiro-lactam NMDA receptor modulators and their use
IL276330A (en) Spiro-lactam NMDA receptor modulators and their use
IL240166A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240164A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
EP3490994B8 (fr) Modulateurs spiro-lactames et bis-spiro-lactames des récepteurs nmda et leurs utilisations
IL240163B (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240162A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240165A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
LT3386591T (lt) Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
EP3558318A4 (fr) Modulateurs des récepteurs nmda et utilisations de ceux-ci
HK1245259A1 (zh) 作為nmda受體調節劑的吡啶並嘧啶酮類及它們的用途